451 related articles for article (PubMed ID: 31468240)
21. Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.
Yin Q; Xu H; Zhong Y; Ni J; Hu S
BMC Cancer; 2022 Feb; 22(1):163. PubMed ID: 35148700
[TBL] [Abstract][Full Text] [Related]
22. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
Zhu H; Zhao S; Zuo C; Ren F
AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
[No Abstract] [Full Text] [Related]
23. FDG PET/CT of Chromophobe Renal Cell Carcinoma With Sarcomatoid Differentiation.
Lee CH; Kesari V; Legesse T; Chen W
Clin Nucl Med; 2018 May; 43(5):367-369. PubMed ID: 29485439
[TBL] [Abstract][Full Text] [Related]
24. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development.
Khandani AH; Rathmell WK
Semin Nucl Med; 2012 Jul; 42(4):221-30. PubMed ID: 22681671
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma.
Jadvar H; Kherbache HM; Pinski JK; Conti PS
Clin Nephrol; 2003 Dec; 60(6):395-400. PubMed ID: 14690256
[TBL] [Abstract][Full Text] [Related]
26. [The Usefulness of 11C-Choline PET/CT for Detecting Metastasis and Treatment Monitoring of Renal Cell Carcinoma : Report of Two Cases].
Nakanishi Y; Taguchi M; Oshima K; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamamoto S; Kitajima K; Yamakado K
Hinyokika Kiyo; 2018 Aug; 64(8):339-343. PubMed ID: 30369223
[TBL] [Abstract][Full Text] [Related]
27. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
28. Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT.
García Garzon JR; Bassa P; Llinares E; Soler M; Moragas M; Riera E
Clin Nucl Med; 2015 Nov; 40(11):910-1. PubMed ID: 26252325
[TBL] [Abstract][Full Text] [Related]
29. Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma?
Mennitto A; Grassi P; Verzoni E; Ratta R; Procopio G
J Med Imaging Radiat Oncol; 2017 Apr; 61(2):250-251. PubMed ID: 28070961
[No Abstract] [Full Text] [Related]
30. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
[TBL] [Abstract][Full Text] [Related]
31. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
32. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
33. Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.
Harrison MR; George DJ
Clin Cancer Res; 2011 Sep; 17(18):5841-3. PubMed ID: 21926167
[TBL] [Abstract][Full Text] [Related]
34. Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.
Park S; Lee HY; Lee S
J Cancer Res Clin Oncol; 2022 Jan; 148(1):215-224. PubMed ID: 34106327
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
Elahmadawy MA; Elazab MSS; Ahmed S; Salama M
Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347
[TBL] [Abstract][Full Text] [Related]
36. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study.
Minamimoto R; Nakaigawa N; Nagashima Y; Toyohara J; Ueno D; Namura K; Nakajima K; Yao M; Kubota K
Abdom Radiol (NY); 2016 Mar; 41(3):521-30. PubMed ID: 27039323
[TBL] [Abstract][Full Text] [Related]
37. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
Bouchelouche K; Choyke PL
PET Clin; 2015 Jul; 10(3):361-74. PubMed ID: 26099672
[TBL] [Abstract][Full Text] [Related]
38. Lesion detection by [
Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
40. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
